ImmunityBio (NASDAQ:IBRX) Stock Purchase Reported by Rep. Lisa C. McClain

Representative Lisa C. McClain (Republican-Michigan) recently bought shares of ImmunityBio, Inc. (NASDAQ:IBRX). In a filing disclosed on October 12th, the Representative disclosed that they had bought between $1,001 and $15,000 in ImmunityBio stock on September 28th. The trade occurred in the Representative’s “CHARLES SCHWAB 401K (HANTZ) > SCHWAB 824” account.

Representative Lisa C. McClain also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of Microsoft (NASDAQ:MSFT) on 9/30/2026.
• Purchased $1,001 – $15,000 in shares of ImmunityBio (NASDAQ:IBRX) on 9/30/2026.
• Sold $15,001 – $50,000 in shares of Seagate Technology (NASDAQ:STX) on 9/30/2026.
• Purchased $1,001 – $15,000 in shares of Caterpillar (NYSE:CAT) on 9/28/2026.
• Purchased $15,001 – $50,000 in shares of Olin (NYSE:OLN) on 9/14/2026.
• Purchased $1,001 – $15,000 in shares of Novagold Resources (NYSEAMERICAN:NG) on 9/14/2026.
• Purchased $15,001 – $50,000 in shares of Transocean (NYSE:RIG) on 9/14/2026.
• Purchased $15,001 – $50,000 in shares of CACI International (NYSE:CACI) on 9/14/2026.

ImmunityBio Stock Performance

Shares of NASDAQ:IBRX opened at $9.80 on Wednesday. The firm has a market cap of $10.39 billion, a price-to-earnings ratio of -10.10 and a beta of 0.02. The business has a 50-day simple moving average of $8.43 and a two-hundred day simple moving average of $7.92. ImmunityBio, Inc. has a fifty-two week low of $1.95 and a fifty-two week high of $12.43.

ImmunityBio (NASDAQ:IBRX) last announced its quarterly earnings results on Tuesday, August 4th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.14). The firm had revenue of $51.24 million for the quarter, compared to analysts’ expectations of $49.70 million. As a group, research analysts predict that ImmunityBio, Inc. will post -0.44 earnings per share for the current year.

Insider Activity at ImmunityBio

In other news, Director Cheryl Cohen sold 81,056 shares of the firm’s stock in a transaction on Friday, October 2nd. The shares were sold at an average price of $10.50, for a total transaction of $851,088.00. Following the sale, the director directly owned 100,309 shares in the company, valued at $1,053,244.50. This trade represents a 44.69% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Barry J. Simon sold 25,000 shares of the firm’s stock in a transaction dated Monday, October 5th. The shares were sold at an average price of $10.75, for a total value of $268,750.00. Following the sale, the director directly owned 2,777,788 shares in the company, valued at approximately $29,861,221. This represents a 0.89% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 66.10% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Markowski Investments bought a new position in ImmunityBio in the 2nd quarter worth $29,000. GAMMA Investing LLC lifted its position in shares of ImmunityBio by 262.2% during the 3rd quarter. GAMMA Investing LLC now owns 3,807 shares of the company’s stock valued at $36,000 after buying an additional 2,756 shares in the last quarter. Geneos Wealth Management Inc. lifted its position in shares of ImmunityBio by 579.3% during the 1st quarter. Geneos Wealth Management Inc. now owns 5,754 shares of the company’s stock valued at $44,000 after buying an additional 4,907 shares in the last quarter. Western Wealth Management LLC bought a new position in shares of ImmunityBio during the 1st quarter valued at approximately $44,000. Finally, Hollencrest Capital Management bought a new position in shares of ImmunityBio during the 2nd quarter valued at approximately $44,000. 8.58% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of research analysts recently weighed in on the stock. Jefferies Financial Group upgraded shares of ImmunityBio to a “strong-buy” rating in a research report on Friday, September 25th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of ImmunityBio in a research report on Tuesday, October 6th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $14.20.

About Representative McClain

Lisa McClain (Republican Party) is a member of the U.S. House, representing Michigan’s 9th Congressional District. She assumed office on January 3, 2023. Her current term ends on January 3, 2027.

McClain (Republican Party) is running for re-election to the U.S. House to represent Michigan’s 9th Congressional District. She declared candidacy for the 2026 election.

Lisa McClain lives in Romeo, Michigan. McClain earned a bachelor’s degree in business administration from Northwood University. Her career experience includes founding and working as the president of North End Support Team.

About ImmunityBio

ImmunityBio, Inc is a biotechnology company focused on developing and commercializing immunotherapies designed to activate and strengthen the body’s immune system against cancer and infectious diseases. The company combines cytokine-based therapies, vaccines, cellular therapies and other immune-modulating technologies in an effort to create durable treatment responses.

Its lead product, ANKTIVA (nogapendekin alfa inbakicept-pmln), is an interleukin-15 receptor agonist immune stimulator.